Search results
Lilly Agrees to Buy US Biotech Morphic in $3.2 Billion Deal
Bloomberg· 12 hours agoEli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about $3.2 billion to...
FDA approves Eli Lilly's treatment which slows symptoms down
Daily Mail· 6 days agoThe US FDA has approved donanemab, a treatment for Alzheimer's disease that helps the body remove...
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Zacks via Yahoo Finance UK· 5 days agoEli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be...
FDA approves second Alzheimer’s drug that can modestly slow disease
Express and Star· 6 days agoThe Food and Drug Administration (FDA) approved Eli Lilly’s Kisunla, known chemically as donanemab,...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease | CNN
CNN.com· 6 days agoThe US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to...
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024
Associated Press via Yahoo Finance UK· 6 days agoDigital-media conglomerate IAC is reportedly considering a bid to take control of the owner of CBS and Paramount Studio. Eli Lilly and Co., down $7.66 to ...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 5 days agoDonanemab, or Kisunla, is the third drug approved to target one of the causes of Alzheimer’s: the...
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Zacks via Yahoo Finance UK· 3 days agoEli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi...
Second drug that slows Alzheimer's approved for use in USA
Liverpool Echo via Yahoo News UK· 6 days agoThe Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of...
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Zacks via Yahoo Finance UK· 8 hours agoThis ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at...